StreetInsider.com News Articles

Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Model Updates

Mon, 20 Jul 2026 07:26:59 -0400

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $120.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "We are updating our model for 2Q. Management raised annual Adjusted EPS guidance to $5.45-5.60 (was $5.38- 5.58) and maintained annual comparable revenue growth expectations of 6.5-7.5%. Comparable growth excludes foreign currency impact and rebases the prior year for the Exact Sciences acquisition. We are raising our 2026 revenue forecast to $50.194 billion from $49.963 billion and our Adjusted EPS estimate rises to $5.53 from $5.48 a share. We assume comparable revenue growth of 6.6% and foreign currency exchange impact

Abbott Labs (ABT) PT Raised to $117 at Bernstein SocGen Group

Fri, 17 Jul 2026 08:48:39 -0400

Bernstein SocGen Group analyst Lee Hambright raised the price target on Abbott Labs (NYSE: ABT) to $117.00 (from $110.00) while maintaining a Outperform rating.

Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Revenue Beat

Fri, 17 Jul 2026 07:36:04 -0400

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $120.00 price target on Abbott Labs (NYSE: ABT).

The analyst commented, "Abbott Labs reported 2Q Adjusted EPS of $1.31 on revenue of $12.593 Billion, which was ahead of our estimates of $1.28 / $12.603 Billion and Consensus of $1.28 / $12.523 Billion, respectively. The company had guided to 2Q Adjusted EPS of $1.25 to $1.31. Management raised annual Adjusted EPS guidance to $5.45-5.60 (was $5.38-5.58) and maintained annual comparable revenue growth expectations of 6.5-7.5%. Comparable growth excludes foreign currency impact and rebases the prior year for the Exact Sciences acquisition. Growth

Abbott Labs (ABT) PT Raised to $120 at JPMorgan

Fri, 17 Jul 2026 07:24:56 -0400

JPMorgan analyst Robbie Marcus raised the price target on Abbott Labs (NYSE: ABT) to $120.00 (from $110.00) while maintaining a Overweight rating.

Abbott Labs (ABT) PT Raised to $118 at Piper Sandler

Fri, 17 Jul 2026 06:46:43 -0400

Piper Sandler analyst Adam Maeder raised the price target on Abbott Labs (NYSE: ABT) to $118.00 (from $115.00) while maintaining a Overweight rating.

Abbott Labs (ABT) PT Raised to $112 at Wells Fargo

Fri, 17 Jul 2026 06:42:18 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on Abbott Labs (NYSE: ABT) to $112.00 (from $109.00) while maintaining a Overweight rating.

Abbott Labs (ABT) PT Raised to $134 at BTIG

Thu, 16 Jul 2026 16:00:55 -0400

(Updated - July 16, 2026 4:00 PM EDT)

BTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $134.00 (from $131.00) while maintaining a Buy rating.

The analyst commented: "Abbott shares were up ~11% in Thursday trading following a solid Q2 result, maintained 2026 sales guide, and increased full-year adj. EPS outlook that demonstrated broad-based strength and added confidence to the 2H26 outlook (see our flash note on Q2 headline results here). Importantly, management emphasized strong underlying demand for healthcare as a whole with some forward-looking insight from Diagnostic testing volumes and cited robust performance in its U.S.

Abbott Labs (ABT) PT Raised to $134 at BTIG

Thu, 16 Jul 2026 16:00:55 -0400

(Updated - July 16, 2026 4:00 PM EDT)

BTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $134.00 (from $131.00) while maintaining a Buy rating.

Abbott beats second-quarter estimates, raises 2026 guidance

Thu, 16 Jul 2026 07:43:35 -0400

Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

Adjusted earnings per share came in at $1.31, exceeding the analyst estimate of $1.28, as the healthcare company posted revenue of $12.59 billion, surpassing the consensus estimate of $12.52 billion. Revenue increased 13.0% on a reported basis and 4.8% on a comparable basis compared to the same quarter last year.

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint

Abbott beats second-quarter estimates, raises 2026 guidance

Thu, 16 Jul 2026 07:43:35 -0400

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint

Abbott beats second-quarter estimates, raises 2026 guidance

Thu, 16 Jul 2026 07:43:35 -0400

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint

Form 8-K ABBOTT LABORATORIES For: Jul 16

Thu, 16 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260716/26776741.html

Form 8-K ABBOTT LABORATORIES For: Jul 16

Thu, 16 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260716/26776741.html

Abbott (ABT) Tops Q2 EPS by 3c; offers guidance

Thu, 16 Jul 2026 07:32:30 -0400

Abbott (NYSE: ABT) reported Q2 EPS of $1.31, $0.03 better than the analyst estimate of $1.28. Revenue for the quarter came in at $12.59 billion versus the consensus estimate of $12.52 billion.

GUIDANCE:

Abbott sees FY2026 EPS of $5.45-$5.60, versus the consensus of $5.48.

For earnings history and earnings-related data on Abbott (ABT) click here.

Abbott (ABT) Tops Q2 EPS by 3c; offers guidance

Thu, 16 Jul 2026 07:32:30 -0400

Abbott (NYSE: ABT) reported Q2 EPS of $1.31, $0.03 better than the analyst estimate of $1.28. Revenue for the quarter came in at $12.59 billion versus the consensus estimate of $12.52 billion.

GUIDANCE:

Abbott sees FY2026 EPS of $5.45-$5.60, versus the consensus of $5.48.

For earnings history and earnings-related data on Abbott (ABT) click here.

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Thu, 16 Jul 2026 07:30:00 -0400

Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹
Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases